

**EXHIBIT A**

|   |                      |                          |
|---|----------------------|--------------------------|
| <b>Form PTO-1449</b><br><b>U.S. Department of Commerce</b><br><b>Patent and Trademark Office</b><br><b>INFORMATION DISCLOSURE STATEMENT</b><br><b>(Use several sheets if necessary)</b> | Application Number   | 09/888,963 938           |
|   | Filing Date          | June 25, 2001            |
|   | First Named Inventor | Graham P. Allaway et al. |
|   | Art Unit             |                          |
|   | Examiner Name        |                          |
|   | Attorney Docket No.  | 50875-DA/JPW/AG/LAD      |

## U.S. PATENT DOCUMENTS

| Examiner Initials* | Cite No. <sup>1</sup> | Document Number<br>Number-Kind Code <sup>2</sup> (if known) | Publication Date<br>MM-DD-YYYY | Name of Patentee or Applicant of Cited Document |
|--------------------|-----------------------|---|--------------------------------|---|
|                    |                       | U.S. 6,258,527  | 07-10-2001                     | D. Littman et al.                               |
|                    |                       | U.S. 6,258,782  | 07-10-2001                     | S. Barney et al.                                |
|                    |                       | U.S. 6,692,745  | 02-17-2004                     | W.C. Olson et al.                               |
|                    |                       | U.S. 6,972,126  | 12-06-2005                     | G.P. Allaway et al.                             |
|                    |                       | U.S. 5,939,320  | 08-17-1999                     | D. Littman et al.                               |
|                    |                       | U.S. 5,126,433  | 12-21-1989                     | P.J. Maddon et al.                              |
|                    |                       | U.S. 5,071,964  | 12-10-1991                     | M. Dusing et al.                                |
|                    |                       | U.S. 5,091,513  | 02-25-1992                     | J. Huston et al.                                |
|                    |                       | U.S. 5,215,913  | 06-01-1993                     | M.R. Posner et al.                              |
|                    |                       | U.S. 5,225,539  | 07-06-1993                     | G. P. Winter et al.                             |
|                    |                       | U.S. 5,603,933  | 2-18-1997                      | V.A. Dwyer et al.                               |
|                    |                       | U.S. 5,668,149  | 09-16-1997                     | S. Oroszlan et al.                              |
|                    |                       | U.S. 5,817,767  | 10-06-1998                     | G.P. Allaway et al.                             |
|                    |                       | U.S. 5,854,400  | 12-29-1998                     | T. Chang et al.                                 |
|                    |                       | U.S. 4,886,743  | 12-12-1989                     | L.E. Hood et al.                                |
|                    |                       | U.S. 6,100,087  | 08-08-2000                     | J. Rossi et al.                                 |
|                    |                       | U.S. 6,261,763 B1   | 07-17-2001                     | G.P. Allaway et al.                             |
|                    |                       | U.S. 6,930,174  | 08-16-2005                     | M. Samson et al.                                |

## FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. <sup>1</sup> | Foreign Patent Document<br>Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known) | Publication Date<br>MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | T <sup>6</sup> |
|--------------------|-----------------------|--|--------------------------------|---|----------------|
|                    |                       | WO 92/01451  | 02-06-1992                     |   |                |
|                    |                       | WO 95/16789  | 06-22-1995                     |   |                |
|                    |                       | WO 97/28258  | 08-07-1997                     |   |                |
|                    |                       | WO 98/18826  | 05-07-1998                     |   |                |
|                    |                       | WO 01/55439 A1   | 08-02-2001                     |   |                |
|                    |                       | WO 94/22477  | 10-13-1994                     |   |                |

EXAMINER  
SIGNATURE

DATE CONSIDERED

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds of Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English Language Translation is attached.

Applicants: Graham P. Allaway et al.  
 Serial No.: 09/888,938  
 Filed: June 25, 2001  
 Exhibit A

|   |                      |                          |
|---|----------------------|--------------------------|
| <b>Form PTO-1449</b><br><b>U.S. Department of Commerce</b><br><b>Patent and Trademark Office</b><br><b>INFORMATION DISCLOSURE STATEMENT</b><br><b>(Use several sheets if necessary)</b> | Application Number   | 09/888,963               |
|   | Filing Date          | June 25, 2001            |
|   | First Named Inventor | Graham P. Allaway et al. |
|   | Art Unit             |                          |
|   | Examiner Name        |                          |
| Attorney Docket No.   |                      | 50875-DA/JPW/AG/LAD      |

### U.S. PATENT DOCUMENTS

| Examiner Initials* | Cite No. <sup>1</sup> | Document Number<br>Number-Kind Code <sup>2</sup> (if known) | Publication Date<br>MM-DD-YYYY | Name of Patentee or Applicant of Cited Document |
|--------------------|-----------------------|---|--------------------------------|---|
|                    |                       | U.S. 7,118,859  | 10-10-2006                     | V.M. Litwin et al.                              |
|                    |                       | U.S. 2003/0023044   | 01-30-2003                     | Y. Li et al.                                    |
|                    |                       | U.S. 2005/0260565   | 11-24-2005                     | P.W. Gray et al.                                |
|                    |                       | U.S. 2003/0166870   | 09-04-2003                     | L. Wu et al.                                    |
|                    |                       | U.S. 2004/0259785   | 12-23-2004                     | C. Combadiere et al.                            |
|                    |                       | U.S. 2003/0195348   | 10-16-2003                     | C. Combadiere et al.                            |
|                    |                       | U.S. 2003/0096221   | 05-22-2003                     | D. Littman et al.                               |
|                    |                       | U.S. 2003-0003440   | 01-02-2003                     | L. Lopalco et al.                               |
|                    |                       | U.S. 2006/0029932   | 02-09-2006                     | G.P. Allaway et al.                             |
|                    |                       | U.S. 2006/0140977   | 06-29-2006                     | G.P. Allaway et al.                             |
|                    |                       | U.S. 2002/0045161   | 04-18-2002                     | G.P. Allaway et al.                             |
|                    |                       | U.S. 2004-0062767   | 04-01-2004                     | W.C. Olson et al.                               |
|                    |                       | U.S. 2006-0194244   | 08-31-2006                     | G.P. Allaway et al.                             |
|                    |                       | U.S. 2006-0233798   | 10-19-2006                     | G.P. Allaway et al.                             |
|                    |                       |   |                                |   |
|                    |                       |   |                                |   |
|                    |                       |   |                                |   |
|                    |                       |   |                                |   |

### FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. <sup>1</sup> | Foreign Patent Document<br>Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known) | Publication Date<br>MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | T <sup>6</sup> |
|--------------------|-----------------------|--|--------------------------------|---|----------------|
|                    |                       |  |                                |   |                |
|                    |                       |  |                                |   |                |
|                    |                       |  |                                |   |                |
|                    |                       |  |                                |   |                |
|                    |                       |  |                                |   |                |
|                    |                       |  |                                |   |                |
|                    |                       |  |                                |   |                |

**EXAMINER  
SIGNATURE**
**DATE CONSIDERED**

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds of Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English Language Translation is attached.

|   |                      |   |
|---|----------------------|---|
| <b>Form PTO-1449</b><br><b>U.S. Department of Commerce</b><br><b>Patent and Trademark Office</b><br><br><b>INFORMATION DISCLOSURE CITATION</b><br>(Use several sheets if necessary) | Application Number   | 09/888,963                              |
|   | Filing Date          | June 25, 2001                           |
|   | First Named Inventor | Graham P. Allaway et al.                |
|   | Art Unit             |   |
|   | Examiner Name        |   |
|   |                      | Attorney Docket No. 50875-DA/JPW/AG/LAD |

### NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.   | T <sup>2</sup> |
|--------------------|-----------------------|--|----------------|
|                    |                       | Abaza, M.S.I et al., (1992) "Effects Of Amino Acid Substitutions Outside An Antigenic Site On Protein Binding To Monoclonal Antibodies Of Predetermined Specificity Obtained By Peptide Immunization: Demonstration With Region 94-100 (Antigenic Site 3) Of Myoglobin", <i>J. Prot. Chem.</i> 11(5):433-443 |                |
|                    |                       | Alexander, H. et al., (1992) "Altering The Antigenicity Of Proteins", <i>Proc. Natl. Acad. Sci.</i> 89:3352-3356   |                |
|                    |                       | Alkhatib et al., (1996) Abstract At 3rd Conference On Retroviruses   |                |
|                    |                       | Allan, J., (1997) "Human Immunodeficiency Virus-Related Infections In Animal Model Systems", In <i>AIDS: Biology, Diagnosis, Treatment And Prevention</i> , 4th Edition, Lippincott-Raven Publishers, Philadelphia, Pp 15-27   |                |
|                    |                       | Allaway, G.P. et al., (1993) "Synergistic Inhibition Of HIV-1 Envelope-Mediated Cell Fusion By CD4-Based Molecules In Combination With Antibodies To gp120 Or gp41", <i>AIDS Res Hum Retroviruses</i> 9:581-587  |                |
|                    |                       | Allaway, G.P. et al., (1995) "Expression And Characterization Of CD4-IgG <sub>2</sub> , A Novel Heterotetramer That Neutralizes Primary HIV Type 1 Isolates", <i>AIDS Res Hum Retrovirus</i> 11:533-539  |                |
|                    |                       | Amara, A. et al., (1997) "HIV Coreceptor Downregulation As Antiviral Principle: SDF-1 $\alpha$ -Dependent Internalization Of The Chemokine Receptor CXCR4 Contributes To Inhibition Of HIV Replication", <i>J. Exp. Med.</i> 186:139-146   |                |
|                    |                       | Arthos, J. et al., (1989) "Identification Of The Residues In Human CD4 Critical For The Binding Of HIV". <i>Cell</i> 57:469-481  |                |
|                    |                       | Ashorn, P.A. et al., (1990) "Human Immunodeficiency Virus Envelope Glycoprotein/CD4 Mediated Fusion Of Nonprimate Cells With Human Cells", <i>J. Virol.</i> 64:2149-2156   |                |
|                    |                       | Attanasio, R. et al., (1991) "Anti-Idiotypic Antibody Response To Monoclonal Anti-CD4 Preparations In Nonhuman Primate Species", <i>J. Immunol.</i> 146:507-514  |                |
|                    |                       | Baba, M. et al., (1988) "Mechanism Of Inhibitory Effect Of Dextran Sulfate And Heparin On Replication Of Human Immunodeficiency Virus In Vitro", <i>Proc. Natl. Acad. Sci.</i> 85:6132-6136  |                |
|                    |                       | Back, D.J., (1999) "Pharmacological Issues Relating To Viral Resistance", <i>Infection</i> 27(Suppl. 2):S42-S44  |                |
|                    |                       | Baulerle, P.A. And Huttner, W.B., (1987) "Tyrosine Sulfation Is A Trans-Golgi-Specific Protein Modification", <i>Cell. Biol.</i> 105:2655-2663   |                |

**EXAMINER  
SIGNATURE**
**DATE CONSIDERED**

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a checkmark here if English language Translation is attached.

|   |                                 |   |  |                             |                                 |
|---|---------------------------------|---|--|-----------------------------|---------------------------------|
| <b>Form PTO-1449</b>  |                                 | <b>U.S. Department of Commerce<br/>Patent and Trademark Office</b>  |  | <b>Application Number</b>   | <b>09/888,963</b>               |
|   |                                 |   |  | <b>Filing Date</b>          | <b>June 25, 2001</b>            |
|   |                                 |   |  | <b>First Named Inventor</b> | <b>Graham P. Allaway et al.</b> |
|   |                                 |   |  | <b>Art Unit</b>             |                                 |
|   |                                 |   |  | <b>Examiner Name</b>        |                                 |
|   |                                 |   |  | <b>Attorney Docket No.</b>  | <b>50875-DA/JPW/AG/LAD</b>      |
| <b>INFORMATION DISCLOSURE CITATION</b><br>(Use several sheets if necessary)   |                                 |   |  |                             |                                 |
| <b>NON PATENT LITERATURE DOCUMENTS</b>  |                                 |   |  |                             |                                 |
| <b>Examiner<br/>Initials*</b>   | <b>Cite<br/>No.<sup>1</sup></b> | <b>Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.</b> |  |                             | <b>T<sup>2</sup></b>            |
|   |                                 | Benet et al. (1990) "Pharmacokinetics: The Dynamics Of Drug Absorption, Distribution And Elimination" In <i>Goodman And Gilman's The Pharmacological Basis Of Therapeutics</i> , Gilman Et El., Eds. Pergamon Press, New York, Pp 3-32                                |  |                             |                                 |
|   |                                 | Berger, E.A. et al (1996) Abstract No. 002, 8 At Keystone Symposium   |  |                             |                                 |
|   |                                 | Berger, E.A., (1997) "HIV Entry And Tropism: The Chemokine Receptor Connection" <i>AIDS</i> 11(Suppl A):S3-S16  |  |                             |                                 |
|   |                                 | Bieniasz, P.D. et al., (1997) "HIV-1 Induced Cell Fusion Is Mediated By Multiple Regions Within Both The Viral Envelope And The CCR5 Co-Receptor", <i>EMBO</i> 16:2599-2609   |  |                             |                                 |
|   |                                 | Blanpain, C. et al., (1999) "Multiple Charged And Aromatic Residues In CCR5 Amino-Terminal Domain Are Involved In High Affinity Binding Of Both Chemokines And HIV-1 Env Protein", <i>J. Biol. Chem.</i> 274:34719-34727  |  |                             |                                 |
|   |                                 | Brelot, A. et al., (1997) "Role Of The First And Third Extracellular Domains Of CXCR4 In Human Immunodeficiency Virus Coreceptor Activity", <i>J. Virol.</i> 71:4744-4751   |  |                             |                                 |
|   |                                 | Broder, C.C. et al., (1993) "The Block To HIV-1 Envelope Glycoprotein-Mediated Membrane Fusion In Animal Cells Expressing Human CD4 Can Be Overcome By A Human Cell Component(s)", <i>Virol.</i> 193:483-491  |  |                             |                                 |
|   |                                 | Broder, C.C. et al., (1996) "HIV And The 7-Transmembrane Domain Receptors", <i>Pathobiology</i> 64(4):171-179   |  |                             |                                 |
|   |                                 | Burkly, L. et al., (1995) "Synergistic Inhibition Of Human Immunodeficiency Virus Type 1 Envelope Glycoprotein-Mediated Cell Fusion And Infection By An Antibody To CD4 Domain 2 In Combination With Anti-gp-120 Antibodies", <i>J. Virol.</i> 69:4267-4273           |  |                             |                                 |
|   |                                 | Burton, D.R. et al., (1994) "Efficient Neutralization Of Primary Isolates Of HIV-1 By A Recombinant Human Monoclonal Antibody", <i>Science</i> 266:1024-1027  |  |                             |                                 |
|   |                                 | Busso, M. et al., (1991) "HIV-Induced Syncytium Formation Requires The Formation Of Conjugates Between Virus-Infected And Uninfected T-Cells In Vitro", <i>AIDS</i> 5:1425-1432   |  |                             |                                 |
|   |                                 | Camerini, D. et al., (1990) "A CD4 Domain Important For HIV-Mediated Syncytium Formation Lies Outside The Virus Binding Site", <i>Cell</i> 60:747-754   |  |                             |                                 |
|   |                                 | Capon, D.J. et al., (1989) "Designing CD4 Immunoadhesions For AIDS Therapy", <i>Nature</i> 337:525-531  |  |                             |                                 |
| <b>EXAMINER<br/>SIGNATURE</b>   |                                 | <b>DATE CONSIDERED</b>  |  |                             |                                 |
| <p><b>*EXAMINER:</b> Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a checkmark here if English language Translation is attached.</p> |                                 |   |  |                             |                                 |

|   |                      |   |
|---|----------------------|---|
| <b>Form PTO-1449</b><br><b>U.S. Department of Commerce</b><br><b>Patent and Trademark Office</b><br><b>INFORMATION DISCLOSURE CITATION</b><br>(Use several sheets if necessary) | Application Number   | 09/888,963                              |
|   | Filing Date          | June 25, 2001                           |
|   | First Named Inventor | Graham P. Allaway et al.                |
|   | Art Unit             |   |
|   | Examiner Name        |   |
|   |                      | Attorney Docket No. 50875-DA/JPW/AG/LAD |

### NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.            | T <sup>2</sup> |
|--------------------|-----------------------|---|----------------|
|                    |                       | Chams, V. et al., (1992) "Simple Assay To Screen For Inhibitors Of Interaction Between The Human Immunodeficiency Virus Envelope Glycoprotein And Its Cellular Receptor, CD4", <i>Antimicrob Agents Chemother.</i> 36(2):262-272  |                |
|                    |                       | Chan, D.C. et al., (1998) "Evidence That A Prominent Cavity In The Coiled Coil Of HIV Type 1 gp41 Is An Attractive Drug Target", <i>Proc. Natl. Acad. Sci.</i> 95:15613-15617   |                |
|                    |                       | Chan, D.C. et al., (1998) "HIV Entry And Its Inhibition", <i>Cell</i> 93:681-684  |                |
|                    |                       | Charo, I.F. et al., (1994) "Molecular Cloning And Functional Expression Of Two Monocyte Chemoattractant Protein 1 Receptors Reveals Alternative Splicing Of The Carboxyl-Terminal Tails", <i>Proc. Natl. Acad. Sci.</i> 91:2752-2756                                      |                |
|                    |                       | Chen, Z. et al., (1997) "Genetically Divergent Strains Of Simian Immunodeficiency Virus Use CCR5 As A Coreceptor For Entry", <i>J. Virol.</i> 71(4):2705-2714   |                |
|                    |                       | Clapham, P.R. et al., (1989) "Soluble CD4 Blocks The Infectivity Of Diverse Strains Of HIV And SIV For T Cells And Monocytes But Not For Brain And Muscle Cells", <i>Nature</i> 337:368-370   |                |
|                    |                       | Clapham, P.R. et al., (1991) "Specific Cell Surface Requirements For The Infection Of CD4-Positive Cells By Human Immunodeficiency Virus Types 1 And 2 By Simian Immunodeficiency Virus", <i>Virol.</i> 181:703-715   |                |
|                    |                       | Co. M.S. et al., (1991) "Humanized Antibodies For Antiviral Therapy" <i>Proc. Natl. Acad. Sci.</i> 88:2869-2873   |                |
|                    |                       | Combadiere, C. et al., (1995) "Cloning And Functional Expression Of A Human Eosinophil CC Chemokine Receptor", <i>J. Biol. Chem.</i> 270:16941-16494  |                |
|                    |                       | Combadiere, C. et al., (1996) "Cloning And Functional Expression Of CC CKR5, A Human Monocyte CC Chemokine Receptor Selective For MIP-1 $\alpha$ , MIP-1 $\beta$ , And RANTES", <i>J. Leukoc. Biol.</i> 60:147-152  |                |
|                    |                       | Connor, R.I. et al., (1997) "Change In Co-Receptor Use Correlates With Disease Progression In HIV-1 Infected Individuals", <i>J. Exp. Med.</i> 185:621-628  |                |
|                    |                       | Cormier, E. G. et al., (2000) "Specific Interaction Of CCR5 Amino-Terminal Domain Peptides Containing Sulfotyrosines With HIV-1 Envelope Glycoprotein gp120", <i>Proc. Natl. Acad. Sci.</i> 97:5762-5767  |                |
|                    |                       | Crowe, S.M. et al., (1992) "Human Immunodeficiency Virus-Infected Monocyte-Derived Macrophages Express Surface gp120 And Fuse With CD4 Lymphoid Cells In Vitro: A Possible Mechanism Of T Lymphocyte Depletion In Vivo", <i>Clin. Immunol Immunopathol.</i> 65(2):143-151 |                |

**EXAMINER  
SIGNATURE**
**DATE CONSIDERED**

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a checkmark here if English language Translation is attached.

|   |                      |                          |
|---|----------------------|--------------------------|
| <b>Form PTO-1449</b><br><b>U.S. Department of Commerce</b><br><b>Patent and Trademark Office</b><br><b>INFORMATION DISCLOSURE CITATION</b><br>(Use several sheets if necessary) | Application Number   | 09/888,963               |
|   | Filing Date          | June 25, 2001            |
|   | First Named Inventor | Graham P. Allaway et al. |
|   | Art Unit             |                          |
|   | Examiner Name        |                          |
| Attorney Docket No.   |                      | 50875-DA/JPW/AG/LAD      |

### NON PATENT LITERATURE DOCUMENTS

| Examiner Initials <sup>*</sup> | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.   | T <sup>2</sup> |
|--------------------------------|-----------------------|--|----------------|
|                                |                       | Crump, M.P. et al., (1997) "Solution Structure And Basis For Functional Activity Of Stromal-Cell Derived Factor-1: Disassociation Of CXCR4 Activation From Binding And Inhibition Of HIV-1", <i>EMBO</i> 16:6996-7007  |                |
|                                |                       | Cushman, M. et al., (1991) "Preparation And Anti-HIV Activities Of Aurintricarboxylic Acid Fractions And Analogues: Direct Correlation Of Antiviral Potency With Molecular Weight", <i>J. Med. Chem.</i> 34:329-337  |                |
|                                |                       | Dalgleish, A.G. et al., (1984) "The CD4 (T4) Antigen Is An Essential Component Of The Receptor For The AIDS Retrovirus" <i>Nature</i> 312:763-766  |                |
|                                |                       | Dalgleish, A.G., (1995) "HIV And CD26", <i>Nat. Med.</i> 1:881-882   |                |
|                                |                       | De Rossi, A. et al., (1995) "Synthetic Peptides From The Principle Neutralizing Domain Of Human Immunodeficiency Virus Type 1 (HIV-1) Enhance HIV-1 Infection Through A CD4-Dependent Mechanism", <i>Virology</i> 184:187-196  |                |
|                                |                       | Deen, K.C. et al., (1988) "A Soluble Form Of CD4(T4) Protein Inhibits AIDS Virus Infection", <i>Nature</i> 331:82-84   |                |
|                                |                       | Deng, X. et al., (1999) "A Synthetic Peptide Derived From Human Immunodeficiency Virus Type 1 gp120 Downregulates The Expression And Function Of Chemokine Receptors CCR5 And CXCR4 In Monocytes By Activating The 7-Transmembrane G-Protein-Coupled Receptor FPRL1/LXA4R", <i>Blood</i> 94(4):1165-1173 |                |
|                                |                       | Detten, M. et al., (2003) "CCR5 N-Terminus Peptides Enhance X4 HIV-1 Infection By CXCR4 Up-Regulation", <i>Biochem. Biophys. Res. Commun.</i> 307(3)640-646  |                |
|                                |                       | Dikic, I., (1996) "Regulation Of HIV-1 Infection By Chemokine Receptors". <i>Acta Med. Croatica</i> 50:163-168   |                |
|                                |                       | Dimitrov, D.S. et al., (1991) "Initial Stages Of HIV-1 Envelope Glycoprotein-Mediated Cell Fusion Monitored By A New Assay Based On Redistribution Of Fluorescent Dyes", <i>AIDS Res Hum Retroviruses</i> 7(10):799-805  |                |
|                                |                       | Ditzel, H.J. et al., (1998) The CCR5 Receptor Acts As An Alloantigen In CCR5Δ32 Homozygous Individuals: Identification Of Chemokine And HIV-1 Blocking Human Antibodies", <i>Proc. Natl. Acad. Sci.</i> 95(9):5241-5245  |                |
|                                |                       | Donzella, G.A. et al., (1998) "AMD3100, A Small Molecule Inhibitor Of HIV-1 Entry Via The CXCR4 Co-Receptor", <i>Nat. Med.</i> 4:72-77   |                |

**EXAMINER  
SIGNATURE**
**DATE CONSIDERED**

**\*EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a checkmark here if English language Translation is attached.

|   |                      |                          |
|---|----------------------|--------------------------|
| <b>Form PTO-1449</b><br><b>U.S. Department of Commerce</b><br><b>Patent and Trademark Office</b><br><b>INFORMATION DISCLOSURE CITATION</b><br>(Use several sheets if necessary) | Application Number   | 09/888,963               |
|   | Filing Date          | June 25, 2001            |
|   | First Named Inventor | Graham P. Allaway et al. |
|   | Art Unit             |                          |
|   | Examiner Name        |                          |
|   | Attorney Docket No.  | 50875-DA/JPW/AG/LAD      |

### NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. | T <sup>2</sup> |
|--------------------|-----------------------|--|----------------|
|                    |                       | Doranz, B.J. et al., (1997) "Two Distinct CCR5 Domains Can Mediate Co-Receptor Usage By Human Immunodeficiency Virus Type 1", <i>J. Virol.</i> 71:6305-6314  |                |
|                    |                       | Dragic, T. et al., (1992) "Complementation Of Murine Cells For Human Immunodeficiency Virus Envelope/CD4-Mediated Fusion In Human/Murine Heterokaryons", <i>J. Virol.</i> 66(8):4794-4802  |                |
|                    |                       | Dragic, T.V. et al., (1993) "Different Requirements For Membrane Fusion Mediated By The Envelopes Of Human Immunodeficiency Virus Types 1 And 2", <i>J. Virol.</i> 67(4):2355-2359   |                |
|                    |                       | Dragic, T.V. et al., (1995) "Proteinase-Resistant Factors In Human Erythrocyte Membranes Mediate CD-4 Dependent Fusion With Cells Expressing Human Immunodeficiency Virus Type 1 Envelope Glycoproteins", <i>J. Virol.</i> 69:1013-1018                        |                |
|                    |                       | Dragic, T.V. et al., (1998) "Amino-Terminal Substitutions In The CCR5 Coreceptor Impair gp120 Binding And Human Immunodeficiency Virus Type 1 Entry" <i>J. Virol.</i> 72(1):279-285  |                |
|                    |                       | Dragic, T.V. et al., (2000) "A Binding Pocket For A Small Molecule Inhibitor Of HIV-1 Entry Within The Transmembrane Helices Of CCR5", <i>Proc. Natl. Acad. Sci.</i> 97(10):5639-5644  |                |
|                    |                       | Ebadi, M., (1998) "The Pharmacokinetic Basis Of Therapeutics", In CRC Desk Reference Of Clinical Pharmacology, CRC Press LLC, Boca Raton, Pp. 1-7  |                |
|                    |                       | Eckert, D.M. et al., (1999) "Inhibiting HIV-1 Entry: Discovery Of D-Peptide Inhibitors That Target The gp41 Coiled-Coil Pocket", <i>Cell</i> 99:103-115  |                |
|                    |                       | Farzan, M. et al., (1998) "A Tyrosine-Rich Region In The N-Terminus Of CCR5 Is Important For Human Immunodeficiency Virus Type 1 Entry And Mediates Association Between gp120 And CCR5", <i>J. Virol.</i> 72:1160-1164   |                |
|                    |                       | Farzan, M. et al., (1999) "Tyrosine Sulfation Of The Amino-Terminus Of CCR5 Facilitates HIV-1 Entry", <i>Cell</i> 96:667-676   |                |
|                    |                       | Farzan, M. et al., (2000) "A Tyrosine-Sulfated Peptide Based On The N Terminus Of CCR5 Interacts With A CD4-Enhanced Epitope Of The HIV-1 gp 120 Envelope Glycoprotein And Inhibits HIV-1 Entry", <i>J. Biol. Chem.</i> 275:33416-33521                        |                |
|                    |                       | Feng, Y. et al., (1996) Abstract No. 116,21 At Keystone Symposium  |                |
|                    |                       | Ferrer, M. et al., (1999) "Selection Of gp-41 Mediated HIV-1 Cell Entry Inhibitors From Biased Combinatorial Libraries Of Non-Natural Binding Elements", <i>Nature Struct. Biol.</i> 6:953-959   |                |

**EXAMINER  
SIGNATURE**
**DATE CONSIDERED**

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a checkmark here if English language Translation is attached.



|   |                      |                          |
|---|----------------------|--------------------------|
| <b>Form PTO-1449</b><br><b>U.S. Department of Commerce</b><br><b>Patent and Trademark Office</b><br><b>INFORMATION DISCLOSURE CITATION</b><br>(Use several sheets if necessary) | Application Number   | 09/888,963               |
|   | Filing Date          | June 25, 2001            |
|   | First Named Inventor | Graham P. Allaway et al. |
|   | Art Unit             |                          |
|   | Examiner Name        |                          |
|   | Attorney Docket No.  | 50875-DA/JPW/AG/LAD      |

### NON PATENT LITERATURE DOCUMENTS

| Examiner Initials <sup>*</sup> | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.          | T <sup>2</sup> |
|--------------------------------|-----------------------|---|----------------|
|                                |                       | Flexner, C. and Hendrix, C., (1997) "Pharmacology Of Antiretroviral Agents". <i>AIDS: Biology, Diagnosis, Treatment and Prevention</i> . 4th Edition. De Vita V., et al eds., Lippincott-Raven Publishers. Pp. 479-493  |                |
|                                |                       | Fouchier, R.A. et al., (1994) "HIV-1 Macrophage Tropism Is Determined At Multiple Levels Of The Viral Replication Cycle", <i>J. Clin. Invest.</i> 94:1806-1814  |                |
|                                |                       | Fouts, T.R. et al., (1997) "Neutralization Of The Human Immunodeficiency Virus Type 1 Primary Isolate JR-FL By Human Monoclonal Antibodies Correlates With Antibody Binding To The Oligomeric Form Of The Envelope Glycoprotein Complex", <i>J. Virol.</i> 71:2779-2785 |                |
|                                |                       | Freed, E.O. et al., (1991) "Identification Of Conserved Residues In The Human Immunodeficiency Virus Type 1 Principal Neutralizing Determinant That Are Involved In Fusion", <i>AIDS Res. Hum. Retroviruses</i> . 7(10):807-811   |                |
|                                |                       | Fradd, F. and Mary, M.E. (1989) "AIDS Vaccines: An Investor's Guide By Shearman Lehman Hutton", Page 10 (Fig. 2)  |                |
|                                |                       | Frazer, J.K. and Capra, J.D., (1999) "Immunoglobulins: Structure And Function" <i>Fundamental Immunology</i> , 4th Edition, Lippincott-Raven Publishers, Philadelphia, Pp. 37-74  |                |
|                                |                       | Furuta, R.A. et al., (1998) "Capture Of An Early Fusion-Active Conformation Of HIV-1 gp41", <i>Nature Struct. Biol.</i> 5(4):276-279  |                |
|                                |                       | Gait, M.J and Karn, J., (1995) "Progress In Anti-HIV Structure Based Drug Design", <i>Trends Biotechnol.</i> 13:430-438   |                |
|                                |                       | Gauduin, M.C. et al., (1996) "Effective Ex Vivo Neutralization Of Human Immunodeficiency Virus Type 1 in Plasma By Recombinant Immunoglobulin Molecules", <i>J. Virol.</i> 70:2586-2592   |                |
|                                |                       | Gauduin, M.C. et al., (1997) "Passive Immunization With A Human Monoclonal Antibody Protects hu-PBL-SCID Mice Against Challenge By Primary Isolates Of HIV-1", <i>Nat. Med.</i> 3:1389-1393   |                |
|                                |                       | Ghorpade, A. et al, (1998) "Role Of The $\beta$ -Chemokine Receptors CCR3 And CCR5 In Human Immunodeficiency Virus Type 1 Infection Of Monocytes And Microglia", <i>J. Virol.</i> 72:3351-3361  |                |
|                                |                       | Golding, H. et al., (1992) "LFA-1 Adhesion Molecules Are Not Involved In The Early Stages Of HIV-1 env-Mediated Cell Membrane Fusion", <i>AIDS Res. Hum. Retroviruses</i> 8:1593-1598   |                |
|                                |                       | Graham, B.S. et al., (1995) "Candidate AIDS Vaccines", <i>New Engl. J. Med.</i> 333:1331-1339   |                |

**EXAMINER  
SIGNATURE**
**DATE CONSIDERED**

**\*EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a checkmark here if English language Translation is attached.

|  |                                 |   |  |                             |                                 |
|--|---------------------------------|---|--|-----------------------------|---------------------------------|
| <b>Form PTO-1449</b>   |                                 | <b>U.S. Department of Commerce<br/>Patent and Trademark Office</b>  |  | <b>Application Number</b>   | <b>09/888,963</b>               |
|  |                                 |   |  | <b>Filing Date</b>          | <b>June 25, 2001</b>            |
|  |                                 |   |  | <b>First Named Inventor</b> | <b>Graham P. Allaway et al.</b> |
|  |                                 |   |  | <b>Art Unit</b>             |                                 |
|  |                                 |   |  | <b>Examiner Name</b>        |                                 |
|  |                                 |   |  | <b>Attorney Docket No.</b>  | <b>50875-DA/JPW/AG/LAD</b>      |
| <b>INFORMATION DISCLOSURE CITATION</b><br>(Use several sheets if necessary)  |                                 |   |  |                             |                                 |
| <b>NON PATENT LITERATURE DOCUMENTS</b>   |                                 |   |  |                             |                                 |
| <b>Examiner<br/>Initials*</b>  | <b>Cite<br/>No.<sup>1</sup></b> | <b>Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.</b> |  |                             | <b>T<sup>2</sup></b>            |
|  |                                 | Greene, E. et al., (2001) "Anti-CCR5 Antibodies In Sera Of HIV-Positive Individuals", <i>Human Immunol.</i> 62(2):143-145   |  |                             |                                 |
|  |                                 | Harouse, J.M. et al., (1991) "Inhibition Of Entry Of HIV-1 In Neural Cell Lines By Antibodies Against Galactosyl Ceramide", <i>Science</i> , 253:320-323  |  |                             |                                 |
|  |                                 | Harrington, R.D. And Geballe, A.P., (1993) "Cofactor Requirement For Human Immunodeficiency Virus Type 1 Entry Into A CD4-Expressing Human Cell Line", <i>J. Virol</i> 67:5939-5947   |  |                             |                                 |
|  |                                 | Heath, et al., (1997) "Chemokine Receptor Usage By Human Eosinophils. The Importance Of CCR3 Demonstrated Using An Antagonistic Monoclonal Antibody", <i>J. Clin. Invest.</i> 99:178-184  |  |                             |                                 |
|  |                                 | Heidenreich, O. et al., (1995) "Application Of Antisense Technology To Therapeutics", <i>Mol. Med. Today</i> 1:128-133  |  |                             |                                 |
|  |                                 | Hildreth, J.E. et al., (1989) "Involvement Of A Leukocyte Adhesion Receptor (LFA-1) In HIV-Induced Syncytium Formation" <i>Science</i> 244:1075-1078  |  |                             |                                 |
|  |                                 | Hill, C.M. et al., (1998) "The Amino Terminus Of Human CCR5 Is Required For Its Function As A Receptor For Diverse Human And Simian Immunodeficiency Virus Envelope Glycoproteins", <i>Virology</i> 248:357-371   |  |                             |                                 |
|  |                                 | Hirsch, M.S. et al., (1997) "Antiretroviral Therapy" In <i>AIDS: Biology, Diagnosis, Treatment, And Prevention, 4th Edition</i> , Lippincott-Raven Publishers, Philadelphia, Pp. 495-508  |  |                             |                                 |
|  |                                 | Howard, O.M.Z. et al., (1998) "Small Molecule Inhibitor Of HIV-1 Cell Fusion Blocks Chemokine Receptor-Mediated Function", <i>J. Leuk. Biol.</i> 64:6-13  |  |                             |                                 |
|  |                                 | Hwang, S. et al., (1991) "Identification Of The Envelope V3 Loop As The Primary Determinant Of Cell Tropism In HIV-1," <i>Science</i> 253:71-74   |  |                             |                                 |
|  |                                 | Jacobson, J.M. et al., (1993) "Passive Immunotherapy In The Treatment Of Advanced Human Immunodeficiency Virus Infection", <i>J. Infect. Dis.</i> 168:298-305   |  |                             |                                 |
|  |                                 | Jacobson, J. et al., (1999) "Results Of A Phase I Trial Of Single-Dose PRO 542, A Novel Inhibitor Of HIV Entry", Abstracts Of The 39th Interscience Conference On Antimicrobial Agents And Chemotherapy 14  |  |                             |                                 |
|  |                                 | Ji, H. et al., (1999) "Inhibition Of Human Immunodeficiency Virus Type 1 Infectivity By The gp41 Core: Role Of A Conserved Hydrophobic Cavity In Membrane Fusion", <i>J. Virol</i> 73:8578-8586   |  |                             |                                 |
|  |                                 | Jiang, S. et al., (1993) "HIV-1 Inhibition By A Peptide", <i>Nature</i> 365: 113  |  |                             |                                 |
| <b>EXAMINER<br/>SIGNATURE</b>  |                                 | <b>DATE CONSIDERED</b>  |  |                             |                                 |
| <p>*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a checkmark here if English language Translation is attached.</p> |                                 |   |  |                             |                                 |

|  |                          |  |                |                    |            |             |               |                      |                          |          |  |               |  |                     |                     |
|--|--------------------------|--|----------------|--------------------|------------|-------------|---------------|----------------------|--------------------------|----------|--|---------------|--|---------------------|---------------------|
| <b>Form PTO-1449</b><br><br><b>U.S. Department of Commerce</b><br><b>Patent and Trademark Office</b>   |                          | <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%;">Application Number</td> <td>09/888,963</td> </tr> <tr> <td>Filing Date</td> <td>June 25, 2001</td> </tr> <tr> <td>First Named Inventor</td> <td>Graham P. Allaway et al.</td> </tr> <tr> <td>Art Unit</td> <td></td> </tr> <tr> <td>Examiner Name</td> <td></td> </tr> <tr> <td>Attorney Docket No.</td> <td>50875-DA/JPW/AG/LAD</td> </tr> </table> |                | Application Number | 09/888,963 | Filing Date | June 25, 2001 | First Named Inventor | Graham P. Allaway et al. | Art Unit |  | Examiner Name |  | Attorney Docket No. | 50875-DA/JPW/AG/LAD |
| Application Number   | 09/888,963               |  |                |                    |            |             |               |                      |                          |          |  |               |  |                     |                     |
| Filing Date  | June 25, 2001            |  |                |                    |            |             |               |                      |                          |          |  |               |  |                     |                     |
| First Named Inventor   | Graham P. Allaway et al. |  |                |                    |            |             |               |                      |                          |          |  |               |  |                     |                     |
| Art Unit   |                          |  |                |                    |            |             |               |                      |                          |          |  |               |  |                     |                     |
| Examiner Name  |                          |  |                |                    |            |             |               |                      |                          |          |  |               |  |                     |                     |
| Attorney Docket No.  | 50875-DA/JPW/AG/LAD      |  |                |                    |            |             |               |                      |                          |          |  |               |  |                     |                     |
| <b>INFORMATION DISCLOSURE CITATION</b><br>(Use several sheets if necessary)  |                          |  |                |                    |            |             |               |                      |                          |          |  |               |  |                     |                     |
| <b>NON PATENT LITERATURE DOCUMENTS</b>   |                          |  |                |                    |            |             |               |                      |                          |          |  |               |  |                     |                     |
| Examiner Initials*   | Cite No. <sup>1</sup>    | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.   | T <sup>2</sup> |                    |            |             |               |                      |                          |          |  |               |  |                     |                     |
|  |                          | Karwowska, S. et al., (1991) "Passive Immunization For The Treatment And Prevention Of HIV Infection", <i>Biotech. Therap.</i> 2:31-48   |                |                    |            |             |               |                      |                          |          |  |               |  |                     |                     |
|  |                          | Katinger, H., (1994) "Human Monoclonal Antibodies For Passive Immunotherapy Of HIV-1" <i>Antibiot. Chemother.</i> 46:25-37   |                |                    |            |             |               |                      |                          |          |  |               |  |                     |                     |
|  |                          | Keller, P.M. et al., (1977) "A Fluorescence Enhancement Assay Of Cell Fusion" <i>J. Cell Sci.</i> 28:167-177   |                |                    |            |             |               |                      |                          |          |  |               |  |                     |                     |
|  |                          | Kilby, J.M. et al., (1998) "Potent Suppression Of HIV-1 Replication In Humans By T-20, A Peptide Inhibitor Of gp41-Mediated Virus Entry", <i>Nat. Med.</i> 4:1302-1307   |                |                    |            |             |               |                      |                          |          |  |               |  |                     |                     |
|  |                          | Konigs, C. et al. (2000) "Monoclonal Antibody Screening Of Phage-Displayed Random Peptide Library Reveals Mimotopes Of Chemokine Receptor CCR5: Implications For The Tertiary Structure Of The Receptor And For An N-Terminal Binding Site For HIV-1 gp120", <i>Eur. J. Immunol.</i> 30(4):1162-1171   |                |                    |            |             |               |                      |                          |          |  |               |  |                     |                     |
|  |                          | Konishi, K. et al., (2000) "Synthesis Of Peptides Mimicking Chemokine Receptor CCR5 And Their Inhibitory Effects Against HIV-1 Infection", <i>Chem. Pharm. Bull (Tokyo)</i> 48(2):308-309  |                |                    |            |             |               |                      |                          |          |  |               |  |                     |                     |
|  |                          | Koup, R.A. et al., (1996) "Defining Antibody Protection Against HIV-1 Transmission In Hu-PBL-SCID Mice", <i>Immunology.</i> 8:263-268  |                |                    |            |             |               |                      |                          |          |  |               |  |                     |                     |
|  |                          | Kwong P.D. et al., (1998) "Structure Of An HIV gp120 Envelope Glycoprotein In Complex With The CD4 Receptor And Neutralizing Human Antibody", <i>Nature</i> 393:648-659  |                |                    |            |             |               |                      |                          |          |  |               |  |                     |                     |
|  |                          | Laal, S. et al., (1994) "Synergistic Neutralization Of Human Immunodeficiency Virus Type 1 By Combinations Of Human Monoclonal Antibodies", <i>J. Virol</i> 68:4001-4008   |                |                    |            |             |               |                      |                          |          |  |               |  |                     |                     |
|  |                          | Lacasse, R.A. et al., (1999) "Fusion-Competent Vaccines: Broad Neutralization Of Primary Isolates Of HIV", <i>Science</i> 283:357-362  |                |                    |            |             |               |                      |                          |          |  |               |  |                     |                     |
|  |                          | Lee, B. et al., (1999) "Epitope Mapping Of CCR5 Reveals Multiple Conformational States And Distinct But Overlapping Structures Involved In Chemokine Coreceptor Function", <i>J. Biol. Chem.</i> 274:9617-9626   |                |                    |            |             |               |                      |                          |          |  |               |  |                     |                     |
|  |                          | Lehner, T. et al., (2001) "Immunogenicity Of The Extracellular Domains Of C-C Chemokine Receptor 5 And The In Vitro Effects On Simian Immunodeficiency Or HIV Infectivity", <i>J. Immunol.</i> 166(12):7446-7455   |                |                    |            |             |               |                      |                          |          |  |               |  |                     |                     |
|  |                          | Li, A. et al., (1997) "Synergistic Neutralization Of A Chimeric SIV/HIV Type 1 Virus With Combinations Of Human Anti-HIV Type 1 Envelope Monoclonal Antibodies Or Hyperimmune Globulins", <i>AIDS Res. Hum. Retroviruses</i> 13:647-56   |                |                    |            |             |               |                      |                          |          |  |               |  |                     |                     |
| <b>EXAMINER SIGNATURE</b>  |                          | <b>DATE CONSIDERED</b>   |                |                    |            |             |               |                      |                          |          |  |               |  |                     |                     |
| <small>*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a checkmark here if English language Translation is attached.</small> |                          |  |                |                    |            |             |               |                      |                          |          |  |               |  |                     |                     |

|  |                                 |  |  |                             |                                 |
|--|---------------------------------|--|--|-----------------------------|---------------------------------|
| <b>Form PTO-1449</b>   |                                 | <b>U.S. Department of Commerce<br/>Patent and Trademark Office</b>   |  | <b>Application Number</b>   | <b>09/888,963</b>               |
|  |                                 |  |  | <b>Filing Date</b>          | <b>June 25, 2001</b>            |
|  |                                 |  |  | <b>First Named Inventor</b> | <b>Graham P. Allaway et al.</b> |
|  |                                 |  |  | <b>Art Unit</b>             |                                 |
|  |                                 |  |  | <b>Examiner Name</b>        |                                 |
|  |                                 |  |  | <b>Attorney Docket No.</b>  | <b>50875-DA/JPW/AG/LAD</b>      |
| <b>INFORMATION DISCLOSURE CITATION</b>   |                                 |  |  |                             |                                 |
| (Use several sheets if necessary)  |                                 |  |  |                             |                                 |
| <b>NON PATENT LITERATURE DOCUMENTS</b>   |                                 |  |  |                             |                                 |
| <b>Examiner<br/>Initials*</b>  | <b>Cite<br/>No.<sup>1</sup></b> | <b>Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.</b>          |  |                             | <b>T<sup>2</sup></b>            |
|  |                                 | Li, A.H. et al., (1998) "Synergistic Neutralization Of Simian-Human Immunodeficiency Virus SHIV-Vpu+ By Triple And Quadruple Combination Of Human Monoclonal Antibodies And High-Titer Antihuman Immunodeficiency Virus Type 1 Immunoglobulins", <i>J. Virol.</i> 72:3235-3240 |  |                             |                                 |
|  |                                 | Mack, M. et al., (1998) "Aminooxypentane-RANTES Induces CCR5 Internalization But Inhibits Recycling: A Novel Inhibitory Mechanisms Of HIV Infectivity", <i>J. Exp. Med.</i> 187:1215-1224  |  |                             |                                 |
|  |                                 | Maddon, P.J. et al., (1986) "The T4 Gene Encodes The AIDS Virus Receptor And Is Expressed In The Immune System And The Brain", <i>Cell</i> 47:333-348  |  |                             |                                 |
|  |                                 | Markosyan, R.M. et al., (2002) "The Mechanism Of Inhibition Of HIV-1 Entry Env-Mediated Cell-Cell Fusion By Recombinant Cores Of gp41 Ectodomain", <i>Virology</i> 302:174-184   |  |                             |                                 |
|  |                                 | Mateu, M.G. et al. (1992) "Non-Additive Effects Of Multiple Amino Acid Substitutions On Antigen-Antibody Recognition", <i>European J. Immunol.</i> 22(6):1385-1389   |  |                             |                                 |
|  |                                 | Max, E., "Immunoglobulins: Molecular Genetics" Fundamental Immunology, 4th Edition. Lippincott-Raven Publishers, Philadelphia, 1999 Pp. 11-182   |  |                             |                                 |
|  |                                 | Mellors, J.W., (1996) "Closing In On Human Immunodeficiency Virus-1", <i>Nat. Med.</i> 2(3):274-275  |  |                             |                                 |
|  |                                 | Mitsuya, H. et al., (1985) "Protection Of T Cells Against Infectivity And Cytopathic Effect Of HTLV-III In Vitro", <i>Retroviruses In Human Lymphoma Leukemia</i> Japan Sci. Soc. Press, Tokyo/VNU Science Press, Utrecht Pp.277-288   |  |                             |                                 |
|  |                                 | Mittler, R.S. et al. (1989) "Synergism Between HIV gp120 And gp120-Specific Antibody In Blocking Human T. Cell Activation", <i>Science</i> 245:1380-1382   |  |                             |                                 |
|  |                                 | Mohan, P. et al., (1992) "Sulfonic Acid Polymers As A New Class Of Human Immunodeficiency Virus Inhibitors", <i>Antiviral Res.</i> 18:139-150  |  |                             |                                 |
|  |                                 | Nagasawa, T. et al., (1994) "Molecular Cloning And Structure Of A Pre-B-Cell Growth-Stimulating Factor", <i>Proc. Natl. Acad. Sci.</i> 91:2305-2309  |  |                             |                                 |
|  |                                 | Nagashima, K.A. et al., (2001) "Human Immunodeficiency Virus Type 1 Entry Inhibitors PRO 542 And T-20 Are Potently Synergistic In Blocking Virus-Cell And Cell-Cell Fusion", <i>J. Infect. Dis.</i> 183:1121-1125  |  |                             |                                 |
| <b>EXAMINER<br/>SIGNATURE</b>  |                                 | <b>DATE CONSIDERED</b>   |  |                             |                                 |
| <p>*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a checkmark here if English language Translation is attached.</p> |                                 |  |  |                             |                                 |

|   |                                 |   |  |                      |                          |
|---|---------------------------------|---|--|----------------------|--------------------------|
| Form PTO-1449   |                                 | U.S. Department of Commerce<br>Patent and Trademark Office  |  | Application Number   | 09/888,963               |
|   |                                 |   |  | Filing Date          | June 25, 2001            |
| <b>INFORMATION DISCLOSURE CITATION</b><br>(Use several sheets if necessary)   |                                 |   |  | First Named Inventor | Graham P. Allaway et al. |
|   |                                 |   |  | Art Unit             |                          |
|   |                                 |   |  | Examiner Name        |                          |
|   |                                 |   |  | Attorney Docket No.  | 50875-DA/JPW/AG/LAD      |
| <b>NON PATENT LITERATURE DOCUMENTS</b>  |                                 |   |  |                      |                          |
| <b>Examiner<br/>Initials</b>  | <b>Cite<br/>No.<sup>1</sup></b> | <b>Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.</b> |  |                      | <b>T<sup>2</sup></b>     |
|   |                                 | Nakano, T. et al., (1995) "Vascular Smooth Muscle Cell-Derived, Gla-Containing Growth-Potentiating Factor for Ca(2+)-Mobilizing Growth Factors", <i>J. Biol. Chem.</i> 270(11):5702-5705  |  |                      |                          |
|   |                                 | Neote, K. et al., (1993) "Molecular Cloning, Functional Expression, And Signaling Characteristics Of A C-C Chemokine Receptor", <i>Cell</i> 72:415-425  |  |                      |                          |
|   |                                 | O'Brien, W.A. et al., (1990) "HIV-1 Tropism For Mononuclear Phagocytes Can Be Determined By Regions Of gp120 Outside Of The CD4-Binding Domain", <i>Nature</i> 348:69-73  |  |                      |                          |
|   |                                 | Oberg, B. and Vrang, L., (1990) "Screening For New Agents", <i>Eur. J. Clin. Microbiol. Infect. Dis.</i> 9(7):466-471   |  |                      |                          |
|   |                                 | Oppermann, M. (2004) "Chemokine Receptor CCR5: Insights Into Structure, Function, And Regulation", <i>Cell. Signal.</i> 16:1201-1210  |  |                      |                          |
|   |                                 | Parren, P.W. et al., (2001) "Antibody Protects Macaques Against Vaginal Challenge With A Pathogenic R5 Simian/Human Immunodeficiency Virus At Serum Levels Giving Complete Neutralization In Vitro" <i>J. Virol.</i> 75:8340-8347                                     |  |                      |                          |
|   |                                 | Partidos, C. et al., (1992) "The Effect Of Orientation Of Epitopes On The Immunogenicity Of Chimeric Synthetic Peptides Representing Measles Virus Protein Sequences", <i>Molecular Immunology</i> 29(5):651-658  |  |                      |                          |
|   |                                 | Peden, K. et al., (1991) "Changes In Growth Properties On Passage In Tissue Culture Of Viruses Derived From Infectious Molecular Clones Of HIV-1LAI, HIV-1MAL, And HIV-1ELI", <i>Virol.</i> 185:661-672   |  |                      |                          |
|   |                                 | Posner, M.R. et al., (1993) "Neutralization Of HIV-1 By F105, A Human Monoclonal Antibody To The CD4 Binding Site Of gp120", <i>J. Acq. Immune Defic. Synd.</i> 6:7-14  |  |                      |                          |
|   |                                 | Power, C.A. et al., (1995) "Molecular Cloning And Functional Expression Of A Novel CC Chemokine Receptor cDNA From A Human Basophilic Cell Line", <i>J. Biol. Chem.</i> 270:19495-19500   |  |                      |                          |
|   |                                 | Proudfoot, A.E. et al., (1996) "Extension Of Recombinant Human RANTES By The Retention Of The Initiating Methionine Produces A Potent Antagonist", <i>J. Biol. Chem.</i> 271:2599-2603  |  |                      |                          |
|   |                                 | Proudfoot, A.E. et al., (1999) "Chemokine Receptors: Future Therapeutic Targets For HIV?", <i>Biochem. Pharmacol.</i> 57:451-463  |  |                      |                          |
|   |                                 | Proudfoot, A.E. et al., (2000) "The Strategy Of Blocking The Chemokine System To Combat Disease", <i>Immunol. Rev.</i> 177:246-256  |  |                      |                          |
| <b>EXAMINER<br/>SIGNATURE</b>   |                                 | <b>DATE CONSIDERED</b>  |  |                      |                          |
| <p><small>*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a checkmark here if English language Translation is attached.</small></p> |                                 |   |  |                      |                          |

|   |                      |                          |
|---|----------------------|--------------------------|
| <b>Form PTO-1449</b><br><b>U.S. Department of Commerce</b><br><b>Patent and Trademark Office</b><br><br><b>INFORMATION DISCLOSURE CITATION</b><br>(Use several sheets if necessary) | Application Number   | 09/888,963               |
|   | Filing Date          | June 25, 2001            |
|   | First Named Inventor | Graham P. Allaway et al. |
|   | Art Unit             |                          |
|   | Examiner Name        |                          |
|   | Attorney Docket No.  | 50875-DA/JPW/AG/LAD      |

### NON PATENT LITERATURE DOCUMENTS

| Examiner Initials <sup>*</sup> | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. | T <sup>2</sup> |
|--------------------------------|-----------------------|--|----------------|
|                                |                       | Queen, C. et al., (1989) "A Humanized Antibody That Binds To The Interleukin 2 Receptor", <i>Proc. Natl. Acad. Sci</i> 86:10029-10033  |                |
|                                |                       | Rabut, G.E. et al., (1991) "Alanine Substitutions Of Polar And Nonpolar Residues In The Amino-Terminal Domain Of CCR5 Differently Impair Entry Of Macrophage And Dualtropic Isolates Of Human Immunodeficiency Virus Type 1", <i>J. Virol.</i> 72:3464-3468    |                |
|                                |                       | Richman, D.D., (1996) "Antiretroviral Drug-Resistance: Mechanisms, Pathogenesis, Clinical Significance", <i>Antivir. Chemother.</i> 4:383-395  |                |
|                                |                       | Rodriguez, G. et al (1995) "Mediation Of Human Immunodeficiency Virus Type 1 Binding By Interaction Of Cell Surface Heparin Sulfate Proteoglycans With V3 Region Of Envelope gp120-gp41", <i>J. Virol.</i> 69:2233-2239  |                |
|                                |                       | Rucker, J. et al., (1996) "Regions In B-Chemokine Receptors CCR5 And CCR2b That Determine HIV-1 Cofactor Specificity", <i>Cell</i> 87:437-446  |                |
|                                |                       | Ruffing, N. et al., (1998) "CCR5 Has An Expanded Ligand-Binding Repertoire And Is The Primary Receptor Used By MCP-2 On Activated T-Cells", <i>Cell. Immunol.</i> 189:160-168  |                |
|                                |                       | Rudikoff, S. et al., (1982) "Single Amino Acid Substitution Altering Antigen-Binding Specificity", <i>Proc. Natl. Acad. Sci.</i> 79:1979-1983  |                |
|                                |                       | Rusche, J.R. et al., (1988) "Antibodies That Inhibit Fusion Of Human Immunodeficiency Virus-Infected Cells Bind A 24-Amino Acid Sequence Of The Viral Envelope gp120", <i>Proc. Natl. Acad. Sci.</i> 85:3198-3202  |                |
|                                |                       | Sagg, M. (1997) "Clinical Spectrum Of Human Immunodeficiency Virus Diseases" <i>AIDS: Biology, Diagnosis, Treatment And Prevention</i> , Lippincott-Raven Publishers, Philadelphia, Pp. 203-213  |                |
|                                |                       | Sandstorm, E.G. And Kaplan, J.C., (1987) "Antiviral Therapy In AIDS: Clinical Pharmacological Properties And Therapeutic Experience To Date", <i>Drugs</i> 34:372-390  |                |
|                                |                       | Sato, A.I. et al., (1992) "Anti-CD7 Reagents Inhibit HIV-1 Induced Syncytium Formation," International Conference On AIDS. 81. PA5 Poa 2017  |                |
|                                |                       | Sato, A.I. et al., (1994) "Identification Of CD7 Glycoprotein As An Accessory Molecule In HIV-1 Mediated Syncytium Formation And Cell Free Infection", <i>J. Immunol.</i> 152:5142-5152  |                |
|                                |                       | Sato, A.I. et al., (1995) "A Simple And Rapid Method For Preliminary Evaluation Of In Vivo Efficacy Of Anti-HIV Compounds In Mice", <i>Antivir. Res.</i> 27:151-163  |                |

**EXAMINER  
SIGNATURE**

**DATE CONSIDERED**

**\*EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a checkmark here if English language Translation is attached.

|   |                      |                          |
|---|----------------------|--------------------------|
| <b>Form PTO-1449</b><br><b>U.S. Department of Commerce</b><br><b>Patent and Trademark Office</b><br><b>INFORMATION DISCLOSURE CITATION</b><br>(Use several sheets if necessary) | Application Number   | 09/888,963               |
|   | Filing Date          | June 25, 2001            |
|   | First Named Inventor | Graham P. Allaway et al. |
|   | Art Unit             |                          |
|   | Examiner Name        |                          |
|   | Attorney Docket No.  | 50875-DA/JPW/AG/LAD      |

### NON PATENT LITERATURE DOCUMENTS

| Examiner Initials <sup>*</sup> | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. | T <sup>2</sup> |
|--------------------------------|-----------------------|--|----------------|
|                                |                       | Schanberg, L.W. et al., (1995) "Characterization Of Human CD7 Transgenic Mice", <i>J. Of Immunol.</i> 155: 2407-2418   |                |
|                                |                       | Schmidtayerova, H. et al., (1993) "Characterization Of HIV1-PAR, A Macrophage-Tropic Strain: Cell Tropism, Virus/Cell Entry And Nucleotide Sequence Of The Envelope Glycoprotein. <i>Research In Virology</i> 144(1):21-26                                     |                |
|                                |                       | Schols, D. et al., (1990) "Dextran Sulfate And Other Olyanionic Anti-HIV Compounds Specifically Interact With The Viral gp120 Glycoprotein Expressed By T-Cells Persistently Infected With HIV-1", <i>Virol.</i> 175:556-561                                   |                |
|                                |                       | Schols, D. et al., (1991) "Selective Inhibitory Activity Of Polyhydroxycarboxylates Derived From Phenolic Compounds Against Human Immunodeficiency Virus Replication", <i>J. Acq. Immune Defic. Synd.</i> 4:677-685  |                |
|                                |                       | Schols, D. et al., (1999) "CD26-Processed RANTES(3-68), But Not Intact RANTES, Has Potent Anti-HIV-1 Activity", <i>Antiviral Res.</i> 30:175-187   |                |
|                                |                       | Sinangil, F. et al., (1988) "Quantitative Measurement Of Fusion Between Human Immunodeficiency Virus And Cultured Cells Using Membrane Fluorescence Dequenching", <i>FEB</i> 239(1):88-92  |                |
|                                |                       | Sommerfelt, M.A. et al., (1995) "Intercellular Adhesion Molecule 3, A Candidate Human Immunodeficiency Virus Type 1 Co-Receptor On Lymphoid And Monocytoid Cells", <i>J. Gen. Virol.</i> 76:1345-1352  |                |
|                                |                       | Stein, D.S. et al., (1993) "Immune-Based Therapeutics: Scientific Rationale And Promising Approaches To The Treatment Of The Human Immunodeficiency Virus-Infected Individual", <i>Clin. Infect. Dis.</i> 17:749-771   |                |
|                                |                       | Steinberger, P. et al., (2000) "Generation And Characterization Of A Recombinant Human CCR5-Specific Antibody", <i>J. Biol. Chem.</i> 275:36073-36078  |                |
|                                |                       | Strizki, J.M. et al., (1997) "A Monoclonal Antibody (12G5) Directed Against CXCR4 Inhibits Infection With The Dual-Tropic Human Immunodeficiency Virus Type 1 Isolates HIV-1 89.6 But Not The T-Tropic Isolate HIV-1 Hxb", <i>J. Virol.</i> 71:5678-5683       |                |
|                                |                       | Su, S.B. et al., (1996) "Preparation Of Specific Polyclonal Antibodies To A C-C Chemokine Receptor, CCR1, And Determination Of CCR1 Expression On Various Types Of Leukocytes" <i>J. Leukoc. Biol.</i> 60:658-666  |                |
|                                |                       | Szabo, G. Jr. et al., (1993) "Specific Disengagement Of Cell-Bound Anti-LAM-1 (Anti-Selectin) Antibodies By Aurintricarboxylic Acid," <i>Molecular Immunology</i> 30(18):1689-1694   |                |
|                                |                       | Thali, M. et al., (1992) "Cooperativity Of Neutralizing Antibodies Directed Against The VS And CD4 Binding Regions Of The Human Immunodeficiency Virus gp120 Envelope Glycoprotein", <i>J. Acq. Immune Defic. Synd.</i> 5:591-599                              |                |

**EXAMINER  
SIGNATURE**
**DATE CONSIDERED**

**\*EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a checkmark here if English language Translation is attached.

|   |                      |                          |
|---|----------------------|--------------------------|
| <b>Form PTO-1449</b><br><b>U.S. Department of Commerce</b><br><b>Patent and Trademark Office</b><br><b>INFORMATION DISCLOSURE CITATION</b><br>(Use several sheets if necessary) | Application Number   | 09/888,963               |
|   | Filing Date          | June 25, 2001            |
|   | First Named Inventor | Graham P. Allaway et al. |
|   | Art Unit             |                          |
|   | Examiner Name        |                          |
|   | Attorney Docket No.  | 50875-DA/JPW/AG/LAD      |

### NON PATENT LITERATURE DOCUMENTS

| Examiner Initials <sup>*</sup> | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. | T <sup>2</sup> |
|--------------------------------|-----------------------|--|----------------|
|                                |                       | Tilley, S. A. (1992) "Synergistic Neutralization Of HIV-1 By Human Monoclonal Antibodies Against The V3 Loop And The CD4-Binding Site gp120", <i>AIDS Research And Human Retroviruses</i> 80:4:461-467   |                |
|                                |                       | Tilley, S. A. et al., (1991) "Potent Neutralization Of HIV-1 By Human And Chimpanzee Monoclonal Antibodies Directed Against Three Distinct Epitope Clusters Of gp120", <i>Sixieme Colloque Des Cent Gardes</i> . 211-216                                       |                |
|                                |                       | Travis, B.M. et al., (1992) "Functional Roles Of The V3 Hypervariable Region Of HIV-1 gp160 In The Processing Of gp160 And In The Formation Of Syncytia In CD4-Positive Cells", <i>Virol.</i> 186:313-317  |                |
|                                |                       | Tremblay, C.L. et al. (2000) "Strong In Vitro Synergy Observed Between The Fusion Inhibitor T-20 And A CXCR4 Blocker AMD-3100.", 7th Conference On Retroviruses And Opportunistic Infections Abstract 500  |                |
|                                |                       | Tremblay, C.L. et al., (1999) "Strong In Vitro Synergy Between The Fusion Inhibitor T-20 And The CXCR4 Blocker AMD-3100", <i>J. Acq. Immun. Defici. Synd.</i> 25(2)99-102  |                |
|                                |                       | Trkola, A. et al., (2001) "Potent, Broad-Spectrum Inhibition Of Human Immunodeficiency Virus Type 1 By The CCR5 Monoclonal Antibody PRO 140", <i>J. Virol.</i> 75:579-588  |                |
|                                |                       | Trkola, A et al (1999) "Cross-Clade Neutralization Of Primary Isolates Of Human Immunodeficiency Virus Type 1 By Human Monoclonal Antibodies And Tetrameric CD4-IgG", <i>J. Virol.</i> 69:6609-6617  |                |
|                                |                       | Trkola, A. et al., (1998) "Neutralization Sensitivity Of Human Immunodeficiency Virus Type 1 Primary Isolates To Antibodies And CD4-based Reagents Is Independent Of Coreceptor Usage", <i>J. Virol.</i> 72:1876-1885  |                |
|                                |                       | Tulip, W.R. et al., (1992) "Crystal Structures Of Two Mutant NERAMINIDASE-Antibody Complexes With Amino Acid Substitutions In The Interface", <i>J. Mol. Biol.</i> 227:149-159   |                |
|                                |                       | Valentin, A. et al., (1990) "The Leukocyte Adhesion Glycoprotein CD18 Participates In HIV Induced Syncytia Formation In Monocytoid And T Cells", <i>J. Immunol.</i> 144:934-937  |                |
|                                |                       | Valenzuela, A. et al., (1997) "Neutralizing Antibodies Against The V3 Loop Of Human Immunodeficiency Virus Type 1 Block The CD4-Dependent And Independent Binding Of Virus To Cells", <i>J. Virol.</i> 71(11):8289-8298  |                |
|                                |                       | Vanini, S. et al., (1992) "Discrete Regions Of HIV-1 gp41 Defined By Syncytia-Inhibiting Affinity-Purified Human Antibodies", <i>AIDS</i> 7:167-174  |                |

**EXAMINER  
SIGNATURE**

**DATE CONSIDERED**

**\*EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a checkmark here if English language Translation is attached.



|   |                                 |  |  |                             |                                 |
|---|---------------------------------|--|--|-----------------------------|---------------------------------|
| <b>Form PTO-1449</b>  |                                 | <b>U.S. Department of Commerce<br/>Patent and Trademark Office</b>   |  | <b>Application Number</b>   | <b>09/888,963</b>               |
|   |                                 |  |  | <b>Filing Date</b>          | <b>June 25, 2001</b>            |
|   |                                 |  |  | <b>First Named Inventor</b> | <b>Graham P. Allaway et al.</b> |
|   |                                 |  |  | <b>Art Unit</b>             |                                 |
|   |                                 |  |  | <b>Examiner Name</b>        |                                 |
|   |                                 |  |  | <b>Attorney Docket No.</b>  | <b>50875-DA/JPW/AG/LAD</b>      |
| <b>INFORMATION DISCLOSURE CITATION</b><br>(Use several sheets if necessary)   |                                 |  |  |                             |                                 |
| <b>NON PATENT LITERATURE DOCUMENTS</b>  |                                 |  |  |                             |                                 |
| <b>Examiner<br/>Initials*</b>   | <b>Cite<br/>No.<sup>1</sup></b> | <b>Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.</b>                |  |                             | <b>T<sup>2</sup></b>            |
|   |                                 | Verrier, F.C. et al., (1997) "Antibodies To Several Conformation-Dependent Epitopes Of gp120/gp41 Inhibit CCR-5-Dependent Cell-To-Cell Fusion Mediated By The Native Envelope Glycoprotein Of A Primary Macrophage-Tropic HIV-1 Isolate", <i>Proc. Natl. Acad. Sci.</i> 94:9326-9331 |  |                             |                                 |
|   |                                 | Vijh-Warrier, S, (1996) "Synergistic Neutralization Of Human Immunodeficiency Virus Type 1 By A Chimpanzee Monoclonal Antibody Against The V2 Domain Of gp120 In Combination With Monoclonal Antibodies Against The V3 Loop And The CD4-Binding Site", <i>J. Virol.</i> 70:4466-4473 |  |                             |                                 |
|   |                                 | Vila-Coro, A.J. et al., (2000) "HIV-1 Infection Through The CCR5 Receptor Is Blocked By Receptor Dimerization", <i>Proc. Natl. Acad. Sci.</i> 97(7):3388-3393  |  |                             |                                 |
|   |                                 | Vita, C. et al., (1999) "Rational Engineering Of A Miniprotein That Reproduces The Core Of The CD4 Site Interacting With HIV-1 Envelope Glycoprotein", <i>Proc. Natl. Acad. Sci.</i> 96:13091-13096  |  |                             |                                 |
|   |                                 | Wang, Z.Q. et al., (1994) "Deletion Of T Lymphocytes In Human CD4 Transgenic Mice Induced By HIV-gp120 And gp120-Specific Antibodies From AIDS Patients", <i>Eur. J. Immunol.</i> 24:1553-1557   |  |                             |                                 |
|   |                                 | Wanda, P.E., And Smith, J.D., (1982) "A General Method For Heterokaryon Detection Using Resonance Energy Transfer And A Fluorescence-Activated Cell Sorter", <i>J. Histochem. &amp; Cytochem.</i> 30(12):1297-1300   |  |                             |                                 |
|   |                                 | Weinhold, K.J., et al., (1989) "HIV-1 gp120-Mediated Immune Suppression And Lymphocyte Destruction In The Absence Of Viral Infection", <i>J. Immunol.</i> 142:3091-3097  |  |                             |                                 |
|   |                                 | Wild, C. et al., (1992) "A Synthetic Peptide Inhibitor Of Human Immunodeficiency Virus Replication: Correlation Between Solution Structure And Viral Inhibition", <i>Proc. Natl. Acad. Sci.</i> 89:10537-10541   |  |                             |                                 |
|   |                                 | Wild, C. et al., (1993) "A Synthetic Peptide From HIV-1 gp41 Is A Potent Inhibitor Of Virus Mediated Cell-Cell Fusion", <i>AIDS Res. Hum. Retroviruses</i> 9:1051-1053   |  |                             |                                 |
|   |                                 | Wild, C. et al., (1994) "Peptides Corresponding To A Predictive Alpha-Helical Domain Of Human Immunodeficiency Virus Type 1 gp41 Are Potent Inhibitors Of Virus Infection", <i>Proc. Natl. Acad. Sci.</i> 91:9770-9774   |  |                             |                                 |
|   |                                 | Wild, C. et al., (1995) "The Inhibitory Activity Of An HIV Type 1 Peptide Correlates With Its Ability To Interact With A Leucine Zipper Structure", <i>AIDS Res. Hum. Retroviruses</i> 11:323-325  |  |                             |                                 |
|   |                                 | Yamagami, S. et al., (1994) "cDNA Cloning And Functional Expression Of Human Monocyte Chemoattractant Protein 1 Receptor", <i>Biochem. Biophys. Res. Commun.</i> 212:1156-1162   |  |                             |                                 |
| <b>EXAMINER<br/>SIGNATURE</b>   |                                 | <b>DATE CONSIDERED</b>   |  |                             |                                 |
| <p><b>*EXAMINER:</b> Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a checkmark here if English language Translation is attached.</p> |                                 |  |  |                             |                                 |

|   |                      |                          |
|---|----------------------|--------------------------|
| <b>Form PTO-1449</b><br><b>U.S. Department of Commerce</b><br><b>Patent and Trademark Office</b><br><br><b>INFORMATION DISCLOSURE CITATION</b><br>(Use several sheets if necessary) | Application Number   | 09/888,963               |
|   | Filing Date          | June 25, 2001            |
|   | First Named Inventor | Graham P. Allaway et al. |
|   | Art Unit             |                          |
|   | Examiner Name        |                          |
|   | Attorney Docket No.  | 50875-DA/JPW/AG/LAD      |

### NON PATENT LITERATURE DOCUMENTS

| Examiner<br>Initials <sup>*</sup> | Cite<br>No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.                         | T <sup>2</sup> |
|-----------------------------------|--------------------------|--|----------------|
|                                   |                          | Yarchoan, et al. (1988) "Clinical Aspects of Infection with AIDS Retrovirus: Acute HIV Infection Persistent Generalized Lymphadenopathy and AIDS-Related Complex," <i>AIDS: Etiology, Diagnosis, Treatment and Prevention</i> , Lippincott-Raven Publishers, Philadelphia, pp. 107-109 |                |
|                                   |                          | Yarchoan, R. and Broder, S., (1992) "Correlations Between The In Vitro And The In Vivo Activity Of Anti-HIV Agents: Implications For Future Drug Development", <i>J. Enzyme Inhibit.</i> 6:99-111  |                |
|                                   |                          | Ylisastigui, L. et al., (1998) "Synthetic Full Length And Truncated RANTES Inhibit HIV-1 Infection Or Primary Macrophages", <i>AIDS</i> 12:977-984   |                |
|                                   |                          |  |                |
|                                   |                          |  |                |
|                                   |                          |  |                |
|                                   |                          |  |                |
|                                   |                          |  |                |
|                                   |                          |  |                |
|                                   |                          |  |                |
|                                   |                          |  |                |
|                                   |                          |  |                |
|                                   |                          |  |                |
|                                   |                          |  |                |
|                                   |                          |  |                |

**EXAMINER  
SIGNATURE**

**DATE CONSIDERED**

**\*EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a checkmark here if English language Translation is attached.